Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

RegulatoryZervimesinePositive

AI Analysis

Summary

Cognition Therapeutics scheduled a Type C meeting with the FDA Division of Neurology on October 20th to align on endpoints for the Phase 3 trial of Zervimesine (CT1812) in dementia with Lewy bodies.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Type C Meeting scheduled with FDA Division of Neurology to align on endpoints for Phase 3 trial

Importance:5/10

Sentiment:

0.50

Regulatory MeetingFDANeurologyPhase 3Endpoint DiscussionDLB

Read the original article

Published by GlobeNewswire Pharma on September 29, 2026 11:30 AM

Read Original